LQZ-7F

• CAT Number: I043476
• CAS Number: 354543-09-2
• Molecular Formula: C14H7N9O3
• Molecular Weight: 349.26
• Purity: ≥95%
• Synonyms: 4-amino-N-(13-oxa-10,12,14,16-tetrazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(16),2,4,6,8,10,14-heptaen-8-ylimino)-1,2,5-oxadiazole-3-carboxamide
• InChI: InChI=1S/C14H7N9O3/c15-11-10(20-25-21-11)14(24)19-18-8-6-4-2-1-3-5(6)7-9(8)17-13-12(16-7)22-26-23-13/h1-4H,(H2,15,21)(H,17,23)
• InChIKey: VQFGZNKRRJEBMK-UHFFFAOYSA-N
• SMILES: C1=CC=C2C(=C1)C(=C3C2=NC4=NONC4=N3)N=NC(=O)C5=NON=C5N

LQZ-7F（Cat No.:I043476）is a small molecule inhibitor targeting the protein GSK-3β (glycogen synthase kinase 3 beta), which plays a critical role in various cellular processes, including cell cycle regulation, apoptosis, and metabolism. By inhibiting GSK-3β, LQZ-7F has shown potential in preclinical studies for treating diseases like Alzheimer’s, cancer, and diabetes. The compound’s ability to modulate GSK-3β activity can influence key signaling pathways, providing therapeutic benefits in conditions characterized by abnormal cellular regulation. LQZ-7F is currently being explored for its efficacy in addressing neurodegenerative and metabolic disorders.